Sherbrooke Park Advisers LLC Sells 22,429 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Sherbrooke Park Advisers LLC decreased its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 62.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 13,643 shares of the company's stock after selling 22,429 shares during the quarter. Sherbrooke Park Advisers LLC owned 0.07% of OptimizeRx worth $66,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares in the last quarter. Barclays PLC boosted its position in OptimizeRx by 13.5% in the fourth quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after buying an additional 3,640 shares in the last quarter. Perkins Capital Management Inc. boosted its position in OptimizeRx by 4.4% in the fourth quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock valued at $514,000 after buying an additional 4,450 shares in the last quarter. Geode Capital Management LLC boosted its position in OptimizeRx by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after buying an additional 4,821 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in OptimizeRx in the fourth quarter valued at about $25,000. Institutional investors own 76.47% of the company's stock.

Insider Buying and Selling

In other news, Director James Paul Lang bought 321,408 shares of the stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the purchase, the director now owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.60% of the stock is currently owned by insiders.

OptimizeRx Trading Up 6.2%

Shares of OPRX traded up $0.73 on Tuesday, reaching $12.38. 143,743 shares of the company's stock were exchanged, compared to its average volume of 278,901. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $228.88 million, a P/E ratio of -9.39 and a beta of 1.28. The business has a 50 day moving average price of $9.22 and a two-hundred day moving average price of $6.75. OptimizeRx Co. has a 12 month low of $3.78 and a 12 month high of $13.00.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.19. The business had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. Research analysts anticipate that OptimizeRx Co. will post -0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on OPRX shares. Stifel Nicolaus boosted their price target on shares of OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a research report on Tuesday, May 13th. Citigroup restated an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $10.38.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.